Adalimumab-Induced Lupus Nephritis: Case Report and Review of the Literature

Tumor necrosis factor-alpha inhibitors are known causative agents of systemic lupus erythemato- sus but have rarely been implicated in lupus nephritis. A patient with Crohn's disease on long-term adalimumab treatment presented with new-onset Raynaud's phenomenon and was found to have hemat...

Full description

Saved in:
Bibliographic Details
Published in:European journal of rheumatology 2022-04, Vol.9 (2), p.108-110
Main Authors: Kazzi, Brigitte, Gudenkauf, Brent, Fine, Derek, Monroy-Trujillo, Jose Manuel, Azar, Antoine, Giannini, Gabriel, Timlin, Homa
Format: Article
Language:English
Subjects:
Adalimumab
Case studies
Causes of
Complications and side effects
Lupus
Nephritis
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Tumor necrosis factor-alpha inhibitors are known causative agents of systemic lupus erythemato- sus but have rarely been implicated in lupus nephritis. A patient with Crohn's disease on long-term adalimumab treatment presented with new-onset Raynaud's phenomenon and was found to have hematuria and proteinuria. Elevated antinuclear, anti-dsDNA, and MPO antibodies were found. A renal biopsy confirmed the diagnosis of lupus nephritis. Adalimumab was discontinued ensuing improvement in urine studies and resolution of dsDNA and MPO antibodies. Adalimumab can induce systemic lupus erythematosus and lupus nephritis.
ISSN:2147-9720
2148-4279
DOI:10.5152/eurjrheum.2022.21059